Asia Pacific Organoids and Spheroids Market to Worth over US 1,444.49 Million By 2033 Astute Analytica
ALT Stock | USD 7.11 0.10 1.39% |
Slightly above 61% of Altimmune's investor base is looking to short. The analysis of the overall investor sentiment regarding Altimmune suggests that many traders are alarmed. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.
Altimmune |
Fueled by innovation and rising chronic diseases, organoids and spheroids in Asia Pacific revolutionize personalized medicine, regenerative therapies, and ethical drug testing, with China, India, and Japan spearheading cutting-edge research and applications.New Delhi, Dec. 23, 2024 -- According to the latest study from Astute Analytica research, the Asia Pacific organoids and spheroids market is projected to hit the valuation of US 1,444.49 million by 2033 from US 246.66 milli
Read at finance.yahoo.com
Altimmune Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Altimmune Fundamental Analysis
We analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Altimmune is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Altimmune Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altimmune stock to make a market-neutral strategy. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with similar companies.
Peers
Altimmune Related Equities
VSTM | Verastem | 25.53 | ||||
SAVA | Cassava Sciences | 24.15 | ||||
AVXL | Anavex Life | 13.13 | ||||
RVPH | Reviva Pharmaceuticals | 11.05 | ||||
INMB | INmune Bio | 6.90 | ||||
FBIO | Fortress Biotech | 4.43 | ||||
INZY | Inozyme Pharma | 2.89 | ||||
CABA | Cabaletta Bio | 2.64 | ||||
TERN | Terns Pharmaceuticals | 2.35 | ||||
VKTX | Viking Therapeutics | 2.19 | ||||
ACAD | ACADIA Pharmaceuticals | 1.69 | ||||
MDGL | Madrigal Pharmaceuticals | 1.69 | ||||
HEPA | Hepion Pharmaceuticals | 1.02 | ||||
ARDX | Ardelyx | 0.99 | ||||
AKRO | Akero Therapeutics | 0.93 | ||||
CGTX | Cognition Therapeutics | 0.42 | ||||
DAWN | Day One | 0.32 | ||||
XFOR | X4 Pharmaceuticals | 0.27 | ||||
BIVI | Biovie | 1.83 | ||||
HOOK | Hookipa Pharma | 2.99 | ||||
ZURA | Zura Bio | 6.00 | ||||
ATHA | Athira Pharma | 6.78 |
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.